Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era

Besson, Caroline; Lancar, Rémi; Prévôt, Sophie; Algarte-Génin, Michèle; Delobel, Pierre; Bonnet, Fabrice; Meyohas, Marie-Caroline; Partisani, Marialuisa; Obéric, Lucie; Gabarre, Jean; Goujard, Cécile; Boué, François; Coppo, Paul; Costello, Régis; Hendel-Chavez, Houria; Mekerri, Nawel; Santos, Gabriella Dos; Récher, Christian; Delarue, Richard; Casasnovas, Olivier; Taoufik, Yassine; Mounier, Nicolas; Costagliola, Dominique

doi:10.1097/qad.0000000000001652

Cited by 59 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lymphoma samples studied for the present biological analyses were collected from the 52 HIV‐positive participants newly diagnosed with DLBCL enrolled in The French prospective multicentre cohort study of HIV‐related lymphomas (French National Agency for Research on AIDS and Viral Hepatitis (ANRS)‐CO16 Lymphovir cohort), and treated by R‐CHOP regimen, as previously published (Besson et al , ). Data collected included the patients’ medical history, clinical, biological and histological presentation, and treatment and evolution of NHL and HIV infection.…”

Section: Methodsmentioning

confidence: 99%

“…Data collected included the patients’ medical history, clinical, biological and histological presentation, and treatment and evolution of NHL and HIV infection. (Besson et al , ).…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, immune recovery following cART allows the administration of full‐dose chemotherapy without an excessive risk of fatal infections and has resulted in better outcomes (Antinori et al , ; Besson et al , ; Hoffmann et al , ). Recent studies have demonstrated comparable outcomes for patients with HIV‐associated non‐Hodgkin lymphoma (NHL) and non‐HIV‐infected individuals in the cART era (Boué et al , ; Oriol et al , ; COHERE Study Group et al , ; Dunleavy et al , ; Montoto et al , ; Sparano et al , ; Besson et al , ).…”

mentioning

confidence: 99%

“…Diffuse large B‐cell lymphoma (DLBCL) is the most common histological subtype among NHL in both non‐HIV‐infected and HIV‐infected individuals, comprising 40–50% of people living with HIV (PLHIV) (Bonnet et al , ; Simard & Engels, ; Franceschi et al , ; Achenbach et al , ; Lanoy et al , ; Shiels et al , ; Gopal et al , ; Maso et al , ; Gibson et al , ; Robbins et al , ). Although treatment with standard immunochemotherapy that includes doxorubicin‐based regimens [rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP); or etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R‐EPOCH)] have offered good outcomes with limited toxicity (Kaplan et al , ; Boué et al , ; Ribera et al , ; Wilson et al , ; Dunleavy et al , ; Sparano et al , ; Barta et al , ; Coutinho et al , ; Besson et al , ), NHL is still a leading cause of cancer–related death among HIV‐infected patients. (Bonnet et al , ; Vandenhende et al , ).…”

mentioning

confidence: 99%

“…Several studies have reported independent clinical and biological risk factors for HIV‐infected patients, such as lower CD4 + T‐cell counts, uncontrolled HIV‐1 viral load, age of over 50 years and high International Prognostic Index (IPI) score (Little et al , ; Kaplan et al , ; Mounier et al , ; COHERE Study Group et al , ). Recently, we prospectively showed the negative effect of altered Eastern Cooperative Oncology Group performance status (ECOG PS), the presence of extra‐nodal lymphoma sites, and advanced age‐adjusted IPI (aaIPI) on the survival of HIV‐infected DLBCL patients in the cART era (Besson et al , ).…”

mentioning

confidence: 99%

See 4 more Smart Citations

In situ BCL2 expression is an independent prognostic factor in HIV‐associated DLBCL, a LYMPHOVIR cohort study

et al. 2019

Self Cite

View full text Add to dashboard Cite

The prognostic value of cell of origin (COO) classification and BCL2 expression is not well established in diffuse large B-cell lymphoma (DLBCL) patients with human immunodeficiency virus (HIV) infection in the recent era. Phenotypic patterns were determined by immunohistochemistry (IHC) of pathological samples from patients with HIV-associated DLBCL prospectively enrolled in the French AIDS and Viral Hepatitis CO16 Lymphovir cohort between 2008 and 2015. Molecular subgroup classification into germinal centre B-cell (GCB) and non-GCB subtypes was determined using the Hans algorithm. Among 52 samples of systemic DLBCL subjected to centralized pathological analysis, 25 of the 42 tested for BCL2 expression were positive. Samples were further classified into GCB (n = 19) and non-GCB (n = 16) subtypes and 17 remained unclassified. In multivariable analysis, BCL2 expression was an independent pejorative prognostic biomarker [4-year progression-free survival (PFS): 52% for BCL2 + vs. 88% for BCL2 À , P = 0Á02] and tended to reduce 4-year overall survival (OS) (63% for BCL2 + vs. 88% for BCL2 À , P = 0Á06). The difference between CGB and non-GCB subtypes on PFS and OS did not reach significance (4-year PFS: 79% for GCB vs. 53% for non-GCB, P = 0Á24 and 4-year OS: 78% for GCB vs. 69% for non-GCB, P = 0Á34). BCL2 expression determined by IHC is an independent pejorative prognostic biomarker in HIV-associated DLBCL in the recent era. This supports the investigation of new therapeutic strategies in patients with BCL2 expression.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Data collected included the patients’ medical history, clinical, biological and histological presentation, and treatment and evolution of NHL and HIV infection. (Besson et al , ).…”

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

In situ BCL2 expression is an independent prognostic factor in HIV‐associated DLBCL, a LYMPHOVIR cohort study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

et al. 2020

View full text Add to dashboard Cite

show abstract

Construction and validation of prognostic scoring models to risk stratify patients with acquired immune deficiency syndrome‐related diffuse large B cell lymphoma

Zhao

Liu

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Acquired immune deficiency syndrome (AIDS)-related diffuse large B cell lymphoma (AR-DLBCL) is a rare disease with a high risk of mortality. There is no specific prognostic model for patients with AR-DLBCL. A total of 100 patients diagnosed with AR-DLBCL were enrolled in our study. Clinical features and prognostic factors for overall survival (OS) and progression-free survival (PFS) were evaluated by univariate and multivariate analyses. Central nervous system (CNS) involvement, opportunistic infection (OI) at lymphoma diagnosis, and elevated lactate dehydrogenase (LDH) were selected to construct the OS model; CNS involvement, OI at lymphoma diagnosis, elevated LDH, and over four chemotherapy cycles were selected to construct the PFS model. The area under the curve and C-index of GZMU OS and PFS models were 0.786/0.712; 0.829/0.733, respectively. The models we constructed showed better risk stratification than International Prognostic Index (IPI), age-adjusted IPI, and National Comprehensive Cancer Network-IPI. Furthermore, in combined cohort, the Hosmer−Lemeshow test showed that the models were good fits (OS: p = 0.8244; PFS: p = 0.9968) and the decision curve analysis demonstrated a significantly better net benefit. The prognostic efficacy of the proposed models was validated independently and outperformed the

show abstract

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era

Abstract: In the recent cART era, despite frequent high-risk features, the 2-year overall survival of HIV-DLBCL patients reaches 75%. Outcomes after R-CHOP therapy are similar to those of HIV-negative patients with similar aaIPI.

Cited by 59 publications

References 35 publications

In situ BCL2 expression is an independent prognostic factor in HIV‐associated DLBCL, a LYMPHOVIR cohort study

In situ BCL2 expression is an independent prognostic factor in HIV‐associated DLBCL, a LYMPHOVIR cohort study

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

Construction and validation of prognostic scoring models to risk stratify patients with acquired immune deficiency syndrome‐related diffuse large B cell lymphoma

Contact Info

Product

Resources

About